إعلان
إعلان
ADCT
ADC Therapeutics SA
3.66
USDبرعاية
+0.09
+2.55%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
قبل الإفتتاح
3.71
+0.05
+1.37%
تقارير أرباح ADCT
النسبة الإيجابية المفاجئة
ADCT تفوق 13 من 22 آخر التقديرات.
59%
التقرير التالي
بيانات التقرير القادم
٢٥ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$18.70M
/-$0.29
التغير الضمني من Q3 25 (Revenue/ EPS)
+13.81%
/-3.33%
التغير الضمني من Q4 24 (Revenue/ EPS)
+10.56%
/+3.57%
ADC Therapeutics SA earnings per share and revenue
On ١٠ نوفمبر ٢٠٢٥, ADCT reported earnings of -0.30 USD per share (EPS) for Q3 25, beating the estimate of -0.36 USD, resulting in a 18.68% surprise. Revenue reached 16.43 مليون, compared to an expected 17.42 مليون, with a -5.69% difference. The market reacted with a +4.21% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 المحللين forecast an EPS of -0.29 USD, with revenue projected to reach 18.70 مليون USD, implying an نقصان of -3.33% EPS, and زيادة of 13.81% in Revenue from the last quarter.
الأسئلة الشائعة
What were ADC Therapeutics SA's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, ADC Therapeutics SA reported EPS of -$0.30, beating estimates by 18.68%, and revenue of $16.43M, -5.69% below expectations.
How did the market react to ADC Therapeutics SA's Q3 2025 earnings?
The stock price moved up 4.21%, changed from $4.04 before the earnings release to $4.21 the day after.
When is ADC Therapeutics SA expected to report next?
The next earning report is scheduled for ٢٥ مارس ٢٠٢٦.
What are the forecasts for ADC Therapeutics SA's next earnings report?
Based on 8
المحللين, ADC Therapeutics SA is expected to report EPS of -$0.29 and revenue of $18.70M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان